The company has failed to generate consistent commercial revenue, with recent quarterly net losses reaching $1.7 million as of 2025Q4.
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - |
| Cost of Goods Sold | 392.74K | 745.59K | 769.69K | 604.4K | 26.46K | 9.52K | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - |
| Gross Profit | -392.74K | -745.59K | -769.69K | -604.4K | -26.46K | -9.52K | 0 |
| Gross Margin % | - | - | - | - | - | - | - |
| Gross Profit Growth % | 47.32% | 3.13% | -27.35% | -2184.54% | -178.02% | - | - |
| Operating Expenses | 3.38M | 3.99M | 6.27M | 7.62M | 1.38M | 812.37K | 390.99K |
| OpEx % of Revenue | - | - | - | - | - | - | - |
| Selling, General & Admin | 2.43M | 2.92M | 4.69M | 5.11M | 943.04K | 426.14K | 162.77K |
| SG&A % of Revenue | - | - | - | - | - | - | - |
| Research & Development | 948.29K | 1.07M | 1.58M | 2.51M | 438.32K | 386.23K | 228.22K |
| R&D % of Revenue | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -3.77M | -4.74M | -6.27M | -7.62M | -1.38M | -812.37K | -390.99K |
| Operating Margin % | - | - | - | - | - | - | - |
| Operating Income Growth % | 20.41% | 24.5% | 17.64% | -451.47% | -70.04% | -107.77% | - |
| EBITDA | -3.38M | -3.99M | -5.5M | -7.01M | -1.35M | -802.86K | 0 |
| EBITDA Margin % | - | - | - | - | - | - | - |
| EBITDA Growth % | 15.38% | 27.49% | 21.52% | -417.63% | -68.76% | - | - |
| D&A (Non-Cash Add-back) | 392.74K | 745.59K | 769.69K | 604.4K | 26.46K | 9.52K | 390.99K |
| EBIT | -3.58M | -4.36M | -6.06M | -7.62M | -1.38M | -812.37K | -390.99K |
| Net Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 185.77K | 373.5K | 211.34K | 23.21K | 34.62K | 0 | 0 |
| Pretax Income | -3.58M | -4.36M | -6.06M | -7.59M | -1.35M | -812.37K | -390.99K |
| Pretax Margin % | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | -391 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0.1% |
| Net Income | -3.58M | -4.3M | -5.87M | -7.42M | -1.35M | -812.37K | -390.99K |
| Net Margin % | - | - | - | - | - | - | - |
| Net Income Growth % | 16.68% | 26.73% | 20.9% | -451.16% | -65.78% | -107.77% | - |
| Net Income (Continuing) | -3.58M | -4.36M | -6.06M | -7.59M | -1.35M | -812.37K | -390.99K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | -40.9K | 15.39K | 0 | 0 | 0 |
| EPS (Diluted) | -0.01 | -0.01 | -0.01 | -0.02 | -0.00 | -0.00 | -0.00 |
| EPS Growth % | - | 26.89% | 20.67% | - | - | - | - |
| EPS (Basic) | -0.01 | -0.01 | -0.01 | -0.02 | -0.00 | -0.00 | -0.00 |
| Diluted Shares Outstanding | 494.49M | 494.49M | 494.49M | 494.49M | 480.4M | 480.4M | 480.4M |
| Basic Shares Outstanding | 494.49M | 494.49M | 494.49M | 494.49M | 480.4M | 480.4M | 480.4M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
Clinical Trial Funding Exhaustion
As indicated by the company's historical financial statements, Regencell Bioscience has failed to generate consistent top-line revenue since its inception, with the most recent periods showing zero revenue, underscoring the firm's status as a pre-commercial entity reliant entirely on external capital to sustain its ongoing clinical research operations.
The lack of revenue generation suggests that the company remains in a purely developmental phase, with no clear path to market-ready product sales. Investors should monitor the absence of top-line growth as a primary indicator that the firm has yet to transition from a research-focused organization to a viable commercial enterprise.
Based on reported figures, the company's operating expenses, primarily driven by SG&A and R&D, consistently exceed $1.5 million per quarter, which, when contrasted with the reported $2.4 million cash position, suggests a precarious financial runway that may necessitate immediate and potentially dilutive capital raising activities.
The cost structure appears heavily weighted toward administrative and research overhead rather than direct production costs, which is typical for early-stage biotech. However, the inability to scale these costs efficiently relative to clinical milestones suggests that management may be struggling to maintain expense discipline while awaiting regulatory validation.
According to recent SEC filings, the company's net income remains consistently negative, with quarterly losses frequently exceeding $1.7 million, a trend that highlights the lack of operational earnings quality and the reliance on non-operating adjustments to manage the appearance of the bottom line during this developmental stage.
The presence of stock-based compensation and other non-cash items within the income statement warrants further investigation, as these figures may mask the true extent of the cash burn. The persistent net losses indicate that the company is not yet generating value for shareholders through its core business activities.
As reported in financial statements, the company's reliance on equity-based funding to cover recurring operating losses creates a significant risk of shareholder dilution, particularly given the absence of any revenue-generating milestones that could otherwise provide a buffer against the ongoing depletion of the firm's limited cash reserves.
Short-sellers would likely focus on the widening gap between the company's cash burn and its lack of clinical trial readouts, which suggests that the current valuation may be disconnected from operational reality. The risk of a liquidity crunch appears elevated, as the company has no established debt capacity to bridge the gap between its current state and potential commercialization.
Quick answers to the most common questions about buying RGC stock.
For fiscal year 2025, Regencell Bioscience Holdings Limited (RGC) reported total revenue of $0.0M.
Regencell Bioscience Holdings Limited (RGC) reported a net loss of $3.6M for the fiscal year ending 2025.